The Journal of Immunology, Vol 137, Issue 11 3451-3456, Copyright © 1986 by American Association of Immunologists

ARTICLES

Prazosin treatment during the effector stage of disease suppresses experimental autoimmune encephalomyelitis in the Lewis rat

CF Brosnan, HJ Sacks, RC Goldschmidt, EA Goldmuntz and WT Norton

As part of a study on the role of vasoactive amines in experimental autoimmune encephalomyelitis (EAE), we have found that treatment beginning 7 days post-inoculation (dpi) with the specific alpha 1- adrenoceptor antagonist prazosin can significantly suppress clinical signs of disease in the Lewis rat. In this paper we have addressed the effect of treatment with prazosin commencing at varying times in the disease process. The results show that treatment during the early inductive stage (1 to 6 dpi) has no effect on the clinical course of the disease, whereas treatment commencing at the time of onset of early clinical signs (10 to 16 dpi) still significantly suppresses EAE. Leakage of serum proteins into the central nervous system (CNS) and histologic expression of EAE are also suppressed. Prazosin had no effect on lymphocyte responses to mitogen or antigen as determined by lymphocyte transformation tests when lymphocytes were exposed to prazosin in vitro, and the responses of lymphocytes from prazosin- treated animals were similar to those from saline-treated animals. These results support the hypothesis that prazosin suppresses EAE through a direct vascular effect although they do not preclude an immunologic component to its mechanism of action.

This article has been cited by other articles:

				C. Bolton and C. Paul MK-801 Limits Neurovascular Dysfunction during Experimental Allergic Encephalomyelitis J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 397 - 402. [Abstract] [Full Text]